Patients with Alpha-1 antitrypsin Deficiency due to Null mutations have clinical peculiarities and should require personalized pulmonary management
I. Ferrarotti (Pavia, Italy), S. Ottaviani (Pavia, Italy), E. Paracchini (Veruno, Italy), D. Piloni (Pavia, Italy), F. Mariani (Pavia, Italy), G. Paone (Rome, Italy), A. Balderacchi (Pavia, Italy), V. Barzon (Pavia, Italy), M. Bosio (Pavia, Italy), Z. Kadija (Pavia, Italy), B. Balbi (Veruno, Italy), A. Corsico (Pavia, Italy)
Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Ferrarotti (Pavia, Italy), S. Ottaviani (Pavia, Italy), E. Paracchini (Veruno, Italy), D. Piloni (Pavia, Italy), F. Mariani (Pavia, Italy), G. Paone (Rome, Italy), A. Balderacchi (Pavia, Italy), V. Barzon (Pavia, Italy), M. Bosio (Pavia, Italy), Z. Kadija (Pavia, Italy), B. Balbi (Veruno, Italy), A. Corsico (Pavia, Italy). Patients with Alpha-1 antitrypsin Deficiency due to Null mutations have clinical peculiarities and should require personalized pulmonary management. 4063
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: